Natalizumab [CAS 189261-10-7]
Partner: MedChemexpress LLC
| CAS No: | 189261-10-7 |
| Applications: | COVID-19-immunoregulation |
| MW: | N/A |
| Formula: | N/A |
| SMILES: | [Natalizumab] |
| Purity: | 99.10 |
| Description: | Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to ?4?1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses[1]. |
| Shipping Conditions: | Ship on cold packs |
| Usage: | Research Use Only |
Insight Biotechnology Ltd reserves the right to change pricing without notice
